[
  {
    "ts": null,
    "headline": "Why This Dividend King Still Stands Tall",
    "summary": "With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.",
    "url": "https://finnhub.io/api/news?id=5973ed96ae023ab278b751398deee78fc78bf839eeed69bd26e65f1bea8842d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758756602,
      "headline": "Why This Dividend King Still Stands Tall",
      "id": 136879400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.",
      "url": "https://finnhub.io/api/news?id=5973ed96ae023ab278b751398deee78fc78bf839eeed69bd26e65f1bea8842d8"
    }
  },
  {
    "ts": null,
    "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
    "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758735634,
      "headline": "Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually",
      "id": 136865405,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162606801/image_1162606801.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Takeda offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. Click to read why TAK is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=7ecb21fb8423fde87617c6680b90e9f8522d8dbd7307e733cd3cdfce246117e3"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript",
    "summary": "Johnson & Johnson (NYSE:JNJ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDTCompany ParticipantsTom Cavanaugh - Company...",
    "url": "https://finnhub.io/api/news?id=a409551f4e4f435a37ac964f212893399b06928f3fc2f4985a15eba796e585ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758734261,
      "headline": "Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript",
      "id": 136865243,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson (NYSE:JNJ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 1:10 PM EDTCompany ParticipantsTom Cavanaugh - Company...",
      "url": "https://finnhub.io/api/news?id=a409551f4e4f435a37ac964f212893399b06928f3fc2f4985a15eba796e585ca"
    }
  },
  {
    "ts": null,
    "headline": "As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?",
    "summary": "Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.",
    "url": "https://finnhub.io/api/news?id=cca9dce5b6c09067b1ee76bcb9bc3e5bc30d00c5332230a585e94beab7fa1c69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758733927,
      "headline": "As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?",
      "id": 136866014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Kenvue stock is trailing the broader markets by a wide margin in 2025 due to regulatory concerns over its flagship Tylenol product.",
      "url": "https://finnhub.io/api/news?id=cca9dce5b6c09067b1ee76bcb9bc3e5bc30d00c5332230a585e94beab7fa1c69"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Kings: September 2025",
    "summary": "Discover which Dividend Kings outperformed the SPY in 2024, top stock picks, growth outlooks, and find undervalued opportunities.",
    "url": "https://finnhub.io/api/news?id=3e6cbbdf3db3c5e8c25ad1d3ffcb9866ab9fe4541eb1d96cdb1b4444696daa1f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758728950,
      "headline": "Best Dividend Kings: September 2025",
      "id": 136864560,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156211986/image_2156211986.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover which Dividend Kings outperformed the SPY in 2024, top stock picks, growth outlooks, and find undervalued opportunities.",
      "url": "https://finnhub.io/api/news?id=3e6cbbdf3db3c5e8c25ad1d3ffcb9866ab9fe4541eb1d96cdb1b4444696daa1f"
    }
  },
  {
    "ts": null,
    "headline": "Tylenol maker Kenvue faces mounting crisis after Trump blast",
    "summary": "Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a barrage of litigation over the issue that the company has sought to put behind it.  The US Food and Drug Administration has initiated the process for a label change to products containing acetaminophen that will say the ingredient is associated with a higher risk of autism in children when taken by pregnant women.  If the FDA succeeds in forcing Kenvue to add the autism risks to Tylenol’s label, consumers who sue to hold the company responsible for their child’s autism will likely be able to use the new warnings as evidence in court, plaintiffs’ lawyers say.",
    "url": "https://finnhub.io/api/news?id=6395d731eebf2d8c2c7f8af0bc222e19f04caf34b13087c6ec0dae38464b6efe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758721045,
      "headline": "Tylenol maker Kenvue faces mounting crisis after Trump blast",
      "id": 136862115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Trump’s warnings about the unproven link between Tylenol use during pregnancy to autism in children risks reinvigorating a barrage of litigation over the issue that the company has sought to put behind it.  The US Food and Drug Administration has initiated the process for a label change to products containing acetaminophen that will say the ingredient is associated with a higher risk of autism in children when taken by pregnant women.  If the FDA succeeds in forcing Kenvue to add the autism risks to Tylenol’s label, consumers who sue to hold the company responsible for their child’s autism will likely be able to use the new warnings as evidence in court, plaintiffs’ lawyers say.",
      "url": "https://finnhub.io/api/news?id=6395d731eebf2d8c2c7f8af0bc222e19f04caf34b13087c6ec0dae38464b6efe"
    }
  },
  {
    "ts": null,
    "headline": "Should You Invest in Johnson & Johnson (JNJ) Based on Bullish Wall Street Views?",
    "summary": "Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=4add9da7dc3bd5a6ff20f0b7cd3e312c83578e04920b47aac01353224346e187",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758720603,
      "headline": "Should You Invest in Johnson & Johnson (JNJ) Based on Bullish Wall Street Views?",
      "id": 136861574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=4add9da7dc3bd5a6ff20f0b7cd3e312c83578e04920b47aac01353224346e187"
    }
  },
  {
    "ts": null,
    "headline": "Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures",
    "summary": "SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.",
    "url": "https://finnhub.io/api/news?id=1d4c3e3ff49ae9b5b127c16835c9612adb3754e7b926b5ea70dfb0e6c1346e34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758718140,
      "headline": "Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures",
      "id": 136861575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "SYK posts 11% sales growth and EPS beat for Q2, driven by Mako robotics and MedSurg strength, but faces cost and margin headwinds.",
      "url": "https://finnhub.io/api/news?id=1d4c3e3ff49ae9b5b127c16835c9612adb3754e7b926b5ea70dfb0e6c1346e34"
    }
  },
  {
    "ts": null,
    "headline": "Climate Week NYC 2025 commences with slate of disaster response, green infrastructure deals",
    "summary": "The annual climate event launched with commitments to scale low-carbon cement, boost circularity and supply chain decarbonization and support healthcare workers responding to disasters.",
    "url": "https://finnhub.io/api/news?id=66b63af90d5ebeb5f7c245370d27e697c5dbdae2354b703f5d9fb44eb00306d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758715200,
      "headline": "Climate Week NYC 2025 commences with slate of disaster response, green infrastructure deals",
      "id": 136866005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The annual climate event launched with commitments to scale low-carbon cement, boost circularity and supply chain decarbonization and support healthcare workers responding to disasters.",
      "url": "https://finnhub.io/api/news?id=66b63af90d5ebeb5f7c245370d27e697c5dbdae2354b703f5d9fb44eb00306d0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): Is the Current Valuation Justified After Recent Share Momentum?",
    "summary": "When a household name like Johnson & Johnson (JNJ) makes a move in the market, it is hard not to take notice. Maybe you are wondering if the latest action is a sign of changing sentiment or just routine market noise. The company’s consistent presence in portfolios means any fluctuation gets attention, whether or not it is tied to major headlines. Looking at the bigger picture, Johnson & Johnson’s shares have steadily advanced over the past year, with a strong performance in the past 3 months...",
    "url": "https://finnhub.io/api/news?id=33e3a69868c4d6c80a5c6681ef5a146a4dbb848008daf1531fa269f060164b8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758714691,
      "headline": "Johnson & Johnson (JNJ): Is the Current Valuation Justified After Recent Share Momentum?",
      "id": 136861576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "When a household name like Johnson & Johnson (JNJ) makes a move in the market, it is hard not to take notice. Maybe you are wondering if the latest action is a sign of changing sentiment or just routine market noise. The company’s consistent presence in portfolios means any fluctuation gets attention, whether or not it is tied to major headlines. Looking at the bigger picture, Johnson & Johnson’s shares have steadily advanced over the past year, with a strong performance in the past 3 months...",
      "url": "https://finnhub.io/api/news?id=33e3a69868c4d6c80a5c6681ef5a146a4dbb848008daf1531fa269f060164b8b"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s Abiomed starts third heart pump controller recall since June",
    "summary": "As of Aug. 27, the company had reported five serious injuries and no deaths associated with the issue.",
    "url": "https://finnhub.io/api/news?id=f28565403a7eb14e107d73fee8ace0540a4611ada8e3119e103de8eb93cf0613",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758685273,
      "headline": "J&J’s Abiomed starts third heart pump controller recall since June",
      "id": 136861577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "As of Aug. 27, the company had reported five serious injuries and no deaths associated with the issue.",
      "url": "https://finnhub.io/api/news?id=f28565403a7eb14e107d73fee8ace0540a4611ada8e3119e103de8eb93cf0613"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Impresses with Earnings Beat, Dividend Hike, and Bullish Analyst Target",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a strong positive quarter, the company witnesses a rise in price target and announces new data on its pill. Johnson & Johnson (NYSE: JNJ) reported an EPS of $2.77 for the second quarter of 2025 on July […]",
    "url": "https://finnhub.io/api/news?id=04d30fd63f389b964f68077b583c950dfb7fd5128a6a061e50e56eeacb455347",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758673289,
      "headline": "Johnson & Johnson Impresses with Earnings Beat, Dividend Hike, and Bullish Analyst Target",
      "id": 136858132,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a strong positive quarter, the company witnesses a rise in price target and announces new data on its pill. Johnson & Johnson (NYSE: JNJ) reported an EPS of $2.77 for the second quarter of 2025 on July […]",
      "url": "https://finnhub.io/api/news?id=04d30fd63f389b964f68077b583c950dfb7fd5128a6a061e50e56eeacb455347"
    }
  }
]